Quince Therapeutics Inc., a late-stage biotechnology company, has achieved a significant milestone in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), with over 75% enrollment. Additionally, Quince received FDA Fast Track designation for its eDSP System, designed to treat A-T patients. This designation, based on the potential of eDSP to address high unmet medical needs, facilitates expedited review processes, indicating promising advancements in Quince's efforts to combat this rare neurodegenerative disease. The company plans to submit a New Drug Application to the FDA in the second half of 2026, assuming positive study outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.